Hyuk Kim

Dr. Hyuk Kim

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
HKHyuk Kim
Hyuk Kim
YSYoon E Shin
Yoon E Shin
HYHye-Jin Yoo
Hye-Jin Yoo
JKJae-Young Kim
Jae-Young Kim
JYJeong-Ju Yoo
Jeong-Ju Yoo
YKYoung Don Kim
Young Don Kim
Background and Objectives: Immune check inhibitor (ICI) colitis is one of most common and adverse side effects of ICI. However, there was no case report of ulcerative colitis (UC)-mimicking colitis after atezolizumab use in hepatocellular carcinoma (HCC) to our knowledge. Materials and Methods: We would like to introduce the case of a patient with Stage IV HCC who complained of abdominal pain, diarrhea and rectal bleeding after two cycles of atezolizumab/bevacizumab chemotherapy and was then diagnosed with UC-mimicking colitis. Results: Endoscopy revealed typical findings of UC, suggesting diagnosis of UC-mimicking colitis. The patient was treated with systemic steroids and oral mesalamine, which significantly improved his symptoms, which were also supported by endoscopic findings. The patient resumed chemotherapy with atezolizumab and bevacizumab without any interruption to the chemotherapy schedule. Conclusions: Early endoscopic evaluation is pivotal to diagnosing UC-mimicking colitis. If diagnosed, UC-based treatments such as steroids and mesalamine should be strongly considered. Given previous reports of inflammatory bowel disease (IBD) flare-ups after immunotherapy, routine lower endoscopy, performed together with upper endoscopy before atezolizumab/bevacizumab therapy, is promising to patients.

6 October 2024 in Medicina
Verified
Journal Article
Open access
PDF file
YSYoon-E Shin
Yoon-E Shin
HKHyuk Kim
Hyuk Kim
JYJeong-Ju Yoo
Jeong-Ju Yoo
SKSang Gyune Kim
Sang Gyune Kim
YKYoung Don Kim
Young Don Kim
Background and Objectives: Immune checkpoint inhibitors (ICIs), which target immune checkpoints in cancer cells, are increasingly used as a mainstay in anticancer treatment. The combination of atezolizumab and bevacizumab is also a first-line treatment for hepatocellular carcinoma (HCC). However, ICIs can cause immune-related adverse events (IrAEs) which range from mild to severe, potentially leading to the need for discontinuing immunotherapy. We report a case of a pneumothorax, a rare side effect caused by IrAEs. Materials and Methods: This paper reports a case of a 78-year-old male HCC patient who developed a recurrent pneumothorax, suspected to be an adverse effect of ICIs. Results: The patient was a current smoker with a 30 pack-year smoking history. Prior to initiating ICIs, a chest CT scan showed mild emphysema and fibrosis attributable to smoking. Following ICI treatment, the patient developed a recurrent pneumothorax. Further tests revealed no underlying cause for the pneumothorax other than the ICIs and smoking, and there were no signs of intrapulmonary metastasis or pneumonitis. Conclusions: When a pneumothorax occurs in a patient undergoing immunotherapy, it is important to consider it as a potential adverse effect of the treatment. Special attention should be given to the possibility that immunotherapy may exacerbate underlying lung conditions. Patients should be advised on the importance of smoking cessation. As there are currently no guidelines for resuming immunotherapy after a pneumothorax, it is crucial to weigh the risks and benefits and consider dose reduction or discontinuation of the medication.

25 August 2025 in Gut and Liver
Verified
Journal Article
Open access
PDF file
HCHyun Bin Choi
Hyun Bin Choi
HKHyuk Kim
Hyuk Kim
JYJeong-Ju Yoo
Jeong-Ju Yoo
SKSang Gyune Kim
Sang Gyune Kim
YKYoung Don Kim
Young Don Kim
Hyun Bin Choi, Hyuk Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250227

21 August 2025 in Clinics
Verified
Journal Article
Open access
JYJina Yun
Jina Yun
BKBora Kim
Bora Kim
HKHyuk Kim
Hyuk Kim
SLSung Hee Lim
Sung Hee Lim
SCSeong Hyeok Choi
Seong Hyeok Choi
SPSeong Kyu Park
Seong Kyu Park
Despite the availability of bivalent vaccines targeting both the ancestral SARS-CoV-2 strain and Omicron subvariants, vaccination rates remain low in South Korea. This study aims to evaluate the neutralizing activity against Omicron subvariants following the third SARS-CoV-2 vaccination in patients undergoing chemotherapy, as well as to assess the need for additional vaccinations. Between April and November 2022, the authors assessed the neutralizing activity of the third SARS-CoV-2 vaccine dose in 63 patients undergoing chemotherapy using an ELISA-based surrogate Virus Neutralization Test (sVNT). The authors examined the influence of factors such as prior COVID-19 infection, cancer type (solid vs. hematologic malignancy), type of chemotherapy regimen (cytotoxic chemotherapy, targeted therapy, immune checkpoint inhibitors), and vaccine type (homologous vector, homologous mRNA, heterologous) on neutralizing activity. Among the 57 patients included in the analysis, 26 (45.6 %) had a history of SARS-CoV-2 infection. Patients with hematologic cancers exhibited lower neutralizing antibody responses compared to those with solid tumors for Omicron subvariants BA.1 (24.44 % vs. 71.68 %, p = 0.020), BA.2 (48.22 % vs. 94.59 %, p = 0.006), and BA.4/5 (24.76 % vs. 78.06 %, p = 0.046). Among uninfected patients (n = 31), sVNT inhibition scores were significantly lower across all subvariants (e.g., 5.89 % for BA.1 vs. 58.11 % in infected, p = 0.0025). Treatment delays due to infection were observed in 9 patients (17.75 days on average). Although no deaths were directly attributed to infection, one patient died due to disease progression following a treatment delay caused by the infection. Patients undergoing chemotherapy displayed weak neutralizing responses against Omicron subvariants, especially those with hematologic cancers or no prior infection. Consequently, it is crucial to actively recommend additional vaccinations with bivalent or newly developed vaccines for these vulnerable patients.

10 September 2024 in Journal of the Korean Medical Association
Verified
Journal Article
Open access
PDF file
HKHyuk Kim
Hyuk Kim
JYJeong-Ju Yoo
Jeong-Ju Yoo
Background: This study aimed to summarize evidence of ursodeoxycholic acid (UDCA) use in the management of hepatobiliary diseases, present indications for UDCA use in Korea, and reimbursement criteria for UDCA use in the country.Current Concepts: UDCA is currently approved for the treatment and prevention of gallstone in obese patients with rapid weight loss after post-bariatric surgery, primary biliary cirrhosis (PBC), chronic liver disease with markedly elevated liver function test values, and chronic hepatitis C. However, the approval and reimbursement criteria for UDCA depend on the dose, specific diseases, and circumstances. UDCA is administered at doses of 100, 200, and 300 mg. The 100 mg dose is available over-the-counter, whereas a prescription is required for the 200 and 300 mg doses. The approval standards differed by dose: UDCA 100 mg for biliary diseases and chronic liver disease; UDCA 200 mg for gallstone, PBC, and chronic hepatitis C; and UDCA 300 mg for PBC, gallstone prevention in obese patients, and patients who had undergone gastrectomy. Co-administration of UDCA with antiviral drugs may require patients to bear some costs. UDCA can be combined with either milk thistle or biphenyl dimethyl dicarboxylate but not both.Discussion and Conclusion: UDCA is a relatively safe medication with many benefits. The current reimbursement standards for hepatobiliary diseases include chronic liver disease with elevated liver enzyme levels, gallstone, PBC, chronic hepatitis B, and chronic hepatitis C. Because UDCA is administered at varied doses, it is important to know the appropriate dose and regimen for each condition.

10 September 2026 in Journal of the Korean Medical Association
Verified
Journal Article
Open access
PDF file
HKHyuk Kim
Hyuk Kim
JYJeong-Ju Yoo
Jeong-Ju Yoo
SKSang Gyune Kim
Sang Gyune Kim
YKYoung Don Kim
Young Don Kim
Purpose: Although the liver is widely recognized as the body’s primary metabolic organ, it also functions as a major immunometabolic interface between the gut and systemic circulation. Continuous exposure to gut-derived antigens requires a tightly regulated balance between immune tolerance and immune activation. Therefore, “immune enhancement” should be understood as optimization of the hepatic immune-metabolic network rather than nonspecific stimulation of immune responses. This review summarizes evidence-based strategies for supporting hepatic and systemic immunity in patients with chronic liver disease and in the general population.Current concepts: Hepatic immunity is regulated largely by innate immune components, including Kupffer cells, liver sinusoidal endothelial cells, and Toll-like receptor signaling. The gut–liver axis is a major pathway of immune regulation; probiotics and postbiotics may strengthen the intestinal barrier and reduce lipopolysaccharide-driven inflammation. Nutrients such as branched-chain amino acids, vitamin D, zinc, and selenium support immune-cell function and may help attenuate immunosenescence. Silymarin and melatonin may reduce oxidative stress and modulate nuclear factor κB- and transforming growth factor-β1-mediated inflammatory and fibrotic pathways. Regular moderate exercise and adequate sleep also contribute to immune regulation through anti-inflammatory myokines and circadian stabilization. In cirrhosis-associated immune dysfunction, vaccination against hepatitis A and B, pneumococcus, influenza, and coronavirus disease 2019 is essential for reducing the risk of infection and decompensation.Discussion and conclusion: Maintaining liver health is integral to systemic immune function. A liver-centered strategy that combines gut microbiome modulation, appropriate nutritional supplementation, regular exercise, adequate sleep, and vaccination is preferable to unverified “immune-boosting” supplements.